INS and Hyperglycemia: Two patients in the insulin at entry group (gingival hypertrophy; hyperglycemia), two in the OAD group (arthralgia and myalgia; nausea and vomiting), and eight in the no OAD group (neutropenia; nausea; abdominal pain; pituitary tumor benign; diarrhea; alopecia; subdural hematoma; pregnancy and spontaneous abortion) discontinued because of AEs.